Reviewing Ainos (OTCMKTS:AIMD) and NeuroOne Medical Technologies (NASDAQ:NMTC)

Ainos (OTCMKTS:AIMD) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Insider & Institutional Ownership

0.3% of Ainos shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 4.6% of Ainos shares are owned by company insiders. Comparatively, 7.5% of NeuroOne Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Ainos and NeuroOne Medical Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	0	0	0	0	N/A
NeuroOne Medical Technologies	0	0	0	0	N/A

Volatility and Risk

Ainos has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.

Earnings & Valuation

This table compares Ainos and NeuroOne Medical Technologies’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$65,122.00	68.00	-$14.01 million	($2.55)	-0.27
NeuroOne Medical Technologies	$3.73 million	5.45	-$11.86 million	($0.58)	-1.26

NeuroOne Medical Technologies has higher revenue and earnings than Ainos. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ainos and NeuroOne Medical Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ainos	-515.80%	-44.32%	-40.35%
NeuroOne Medical Technologies	-343.55%	-277.71%	-204.28%

Summary

NeuroOne Medical Technologies beats Ainos on 6 of the 11 factors compared between the two stocks.

About Ainos

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.